These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17514626)

  • 1. Comparison of lipid measures and risk stratification among end-stage renal disease patients.
    Bowden RG; Hebert S; Wilson R; Gentile M; Lanning BA
    J Nephrol; 2007; 20(2):212-8. PubMed ID: 17514626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
    Shelmadine B; Bowden RG; Wilson RL; Beavers D; Hartman J
    Anadolu Kardiyol Derg; 2009 Oct; 9(5):385-9. PubMed ID: 19819789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are the anticardiolipin antibodies a risk factor for coronary artery disease in chronic renal failure patients?
    Ucar E; Kuvandik G; Sert M; Kuvandik C; Temizkan A; Borazan A
    Ren Fail; 2008; 30(8):791-5. PubMed ID: 18791953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.
    Bowden RG; Jitomir J; Wilson RL; Gentile M
    J Ren Nutr; 2009 Jul; 19(4):259-66. PubMed ID: 19539180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
    Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients.
    Bowden RG; La Bounty P; Shelmadine B; Beaujean AA; Wilson RL; Hebert S
    Nephron Clin Pract; 2011; 119(3):c214-9. PubMed ID: 21832847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoperoxidation and hemodialysis.
    Ramos R; Martínez-Castelao A
    Metabolism; 2008 Oct; 57(10):1369-74. PubMed ID: 18803940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-high-density lipoprotein cholesterol in secondary prevention of coronary artery disease: a unique risk factor or redundant information?
    Holcombe SM; Brubaker PH
    J Cardiopulm Rehabil Prev; 2007; 27(6):386-9. PubMed ID: 18197073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of malonyldialdehyde concentration as a product of lipid peroxidation and lipid metabolism in patients on chronic dialysis].
    Miler M; Zamojska S; Fijałkowski P; Lobos M; Paradowski MT
    Pol Merkur Lekarski; 2006 Jun; 20(120):664-7. PubMed ID: 17007263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
    Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
    Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.
    Bowden RG; Wilson RL; Beaujean AA
    J Nephrol; 2011; 24(6):771-7. PubMed ID: 21360474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study.
    Svensson M; Schmidt EB; Jørgensen KA; Christensen JH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2918-24. PubMed ID: 18436564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update.
    Nichols GA; Nag S; Chan W
    Am Heart J; 2007 Sep; 154(3):554-60. PubMed ID: 17719305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.